18 March 2022 | News
Dr. Hansen to provide clinical input to product development process; strengthen strategic partnerships with U.S. networks Second leadership announcement for U.S. subsidiary in a month
Image credit: shutterstock
Seegene Inc. , South Korea's leading molecular diagnostics company, announced the appointment of Dr. Glen Hansen, as the Head of Scientific and Medical Affairs of its United States subsidiary, Seegene Technologies. In this role, Dr. Hansen will provide clinical input to the development process of new products and initiate product and disease state knowledge to targeted medical and scientific thought leaders.
Dr. Hansen's appointment marks the second leadership announcement for the U.S. subsidiary in less than a month. In late February, Seegene appointed Richard Creager, Ph.D., as the CEO to help solidify its U.S. business and deliver on the company's global strategy as a molecular diagnostics platform company, through product development, M&As and strategic alliances.